Latest On Pfizer Inc (PFE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-07-26 05:50 EST | Dividend | A dividend of $0.42 has been announced on Jun 26, 2024. It will be paid Sep 3, 2024 with an ex-dividend date of Jul 26, 2024. | Neutral |  |
| 2024-05-09 05:51 EST | Dividend | A dividend of $0.42 has been announced on Apr 24, 2024. It will be paid Jun 14, 2024 with an ex-dividend date of May 9, 2024. | Neutral | |
| 2024-01-25 04:51 EST | Dividend | A dividend of $0.42 has been announced on Dec 14, 2023. It will be paid Mar 1, 2024 with an ex-dividend date of Jan 25, 2024. | Neutral | |
| 2023-11-09 04:51 EST | Dividend | A dividend of $0.41 has been announced on Oct 4, 2023. It will be paid Dec 4, 2023 with an ex-dividend date of Nov 9, 2023. | Neutral | |
| 2023-07-27 05:52 EST | Dividend | A dividend of $0.41 has been announced on Jun 22, 2023. It will be paid Sep 5, 2023 with an ex-dividend date of Jul 27, 2023. | Neutral | |
About Pfizer Inc (PFE):
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-Tico read more...Vac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
General
- Name Pfizer Inc
- Symbol PFE
- Type Common Stock
- Exchange NYSE
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 78,500
- Last Split Factor1054:1000
- Last Split Date2020-11-17
- Fiscal Year EndDecember
- IPO Date2012-08-13
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.pfizer.com
Valuation
- Trailing PE 20.97
- Forward PE 10.88
- Price/Sales (Trailing 12 Mt.) 4.66
- Price/Book (Most Recent Quarter) 3.06
- Enterprise Value Revenue 5.24
- Enterprise Value EBITDA 16.01
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $3.31
- Next Year EPS Estimate $3.05
- Next Quarter EPS Estimate $0.78
- Profit Margin 23%
- Operating Margin 24%
- Return on Assets 4%
- Return on Equity 11%
- Revenue 41.91 billion
- Earnings Per Share $1.71
- Revenue Per Share $7.54
- Gross Profit 33.33 billion
- Quarterly Earnings Growth -7.9%
ESG Rating
Highlights
- Market Capitalization 199.64 billion
- EBITDA 14.89 billion
- PE Ratio -63.32
- PEG Ratio 2.94
- Analyst Target Price $40.99
- Book Value Per Share $11.36
Share Statistics
- Shares Outstanding 5.58 billion
- Shares Float 5.57 billion
- % Held by Insiders 5%
- % Held by Institutions 69.9%
- Shares Short 67.65 million
- Shares Short Prior Month 63.11 million
- Short Ratio 1.84
- Short % of Float 1%
- Short % of Shares Outstanding 1%
Technicals
- Beta 0.62
- 52 Week High $42.62
- 52 Week Low $25.36
- 50 Day Moving Average 34.7
- 200 Day Moving Average 35.88
Dividends
- Forward Annual Dividend Rate $1.56
- Forward Annual Dividend Yield 4.36%
- Payout Ratio 54%
- Dividend Date 2021-03-05
- ExDividend Date 2021-01-28
- Dividend Per Share $1.52
- Dividend Yield 5.63%
Pfizer Inc (PFE) Dividend Calendar:
Pfizer Inc pays an annual dividend of $1.56 per share, with a dividend yield of 5.63%.
PFE's last dividend payment was made to shareholders on March 5, 2021.
Pfizer Inc pays out 54% of its earnings out as a dividend.
Pfizer Inc (PFE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Pfizer Inc (PFE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Pfizer Inc (PFE) Chart:
Pfizer Inc (PFE) News:
Below you will find a list of latest news for Pfizer Inc (PFE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Pfizer Inc (PFE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest PFE Trades:
Pfizer Inc (PFE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | SC 13D (General statement of acquisition of beneficial ownership) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-30 | 8-K (Current report) | |
| 2020-10-29 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-27 | 8-K (Current report) | |
| 2020-10-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-01 | 4 (Statement of changes in beneficial ownership of securities) | |
Pfizer Inc (PFE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Pfizer Inc (PFE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 5%
Institutional Ownership: 6990%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-27 | PFIZER INC | 10% Share Holder | Buy | 1,200,000.00 | 10.00 | 12,000,000.00 | 27,349,211.00 | |
| 2020-08-06 | RONALD E BLAYLOCK | Director | Buy | 1,500.00 | 38.51 | 57,765.00 | 11,000.00 | |
| 2020-08-06 | RONALD E BLAYLOCK | Director | Buy | 1,000.00 | 38.69 | 38,690.00 | 12,000.00 | |
| 2020-08-06 | RONALD E BLAYLOCK | Director | Buy | 1,000.00 | 38.62 | 38,620.00 | 13,000.00 | |
| 2020-08-06 | RONALD E BLAYLOCK | Director | Buy | 4,000.00 | 38.49 | 153,960.00 | 4,000.00 | |
| 2020-08-06 | RONALD E BLAYLOCK | Director | Buy | 3,000.00 | 38.55 | 115,650.00 | 7,000.00 | |
| 2020-08-06 | RONALD E BLAYLOCK | Director | Buy | 2,500.00 | 38.56 | 96,400.00 | 9,500.00 | |
| 2020-06-05 | JENNIFER B. DAMICO | SVP & Controller | Sell | 2,181.00 | 36.13 | 78,799.53 | 7,542.00 | |
| 2020-06-03 | PFIZER INC | 10% Share Holder | Sell | 370,000.00 | 40.18 | 14,866,600.00 | 2,879,973.00 | |
| 2020-05-18 | Mikael Dolsten | President R&D | Sell | 24,242.00 | 37.79 | 916,105.18 | 174,918.00 | |
| 2020-05-18 | Mikael Dolsten | President R&D | Sell | 17,357.00 | 37.78 | 655,747.46 | 199,160.00 | |
| 2020-05-18 | Mikael Dolsten | President R&D | Sell | 16,840.00 | 37.80 | 636,552.00 | 216,517.00 | |
| 2020-05-18 | Mikael Dolsten | President R&D | Sell | 14,727.00 | 37.77 | 556,238.79 | 233,357.00 | |
| 2020-05-18 | Mikael Dolsten | President R&D | Sell | 9,700.00 | 37.75 | 366,175.00 | 248,084.00 | |
| 2020-05-18 | Mikael Dolsten | President R&D | Sell | 6,470.00 | 37.81 | 244,630.70 | 257,784.00 | |
| 2020-05-18 | Mikael Dolsten | President R&D | Sell | 5,517.00 | 37.76 | 208,321.92 | 264,254.00 | |
| 2020-05-18 | Mikael Dolsten | President R&D | Sell | 500.00 | 37.82 | 18,910.00 | 269,771.00 | |
| 2020-04-29 | DOUGLAS M LANKLER | Executive Vice President | Sell | 7,901.00 | 38.01 | 300,317.01 | 135,375.00 | |
| 2020-04-29 | DAWN ROGERS | Executive Vice President | Sell | 13,000.00 | 38.13 | 495,690.00 | 4,823.00 | |
| 2020-04-29 | RADY A JOHNSON | Executive Vice President | Sell | 13,125.00 | 38.36 | 503,475.00 | 63,940.00 | |